The firm’s intense focus on tenant and operator partnerships produces new off-market investment opportunities, benefiting shareholders. It should see same-store NOI growth above its peers in the ...

A new study finds that combining gelatin sponge with NBCA offers superior control of arterial gastrointestinal bleeding ...

Disney's profit is driven more by its parks and experiences segment than by movie blockbusters. Read why DIS stock is a ...

Follow these 10 steps to build a profitable trading plan. Creating a plan and sticking to it is your key to success in the markets.

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Alternative assets, as a group, performed well in the volatile environment of the first quarter. Ten of the fund’s individual holdings recorded positive returns, while three posted losses.

By combining information from many large datasets, MIT researchers have identified several new potential targets for treating ...

A combination of two drugs could improve outcomes and reduce ... sitting on interview panels for the charity, advising on its five-year strategy, and many more tasks. "We [cancer survivors] all say we ...

A non-inferiority margin of 10% was used for the alternate treatment strategies, as they highlight their potential to increase population-based cure rates for groups that might not have access to a ...

Attempts to compare budesonide/formoterol SMART therapy with regular combination ICS/LABA dosing using other compounds have been confounded by a lack of blinding and unspecified dose adjustment ...

Industry observers have described Penetrium™ as the most clinically advanced ECM-based immunotherapy combination candidate to date, with the potential to serve as a backbone in post-patent ...

With major patent expirations approaching, we are advancing our development strategy to secure global leadership in combination immunotherapy." According to industry analysts, the global immuno ...